Trigger NDCs for CY 2021 (baseline data period - 12/31/2020)

As of reporting year 2022, the MHDO will post a list of NDCs for Manufacturers drug(s) that hit one of the triggers during the prior calendar year as defined in 90-590 CMR Chapter 570, UNIFORM REPORTING SYSTEM FOR PRESCRIPTION DRUG PRICE DATA SETS, section 2 B 1-3.

  1. Increased the wholesale acquisition cost of a brand-name drug by more than 20% per pricing unit;
  2. Increased the wholesale acquisition cost of a generic drug that costs at least $10 per pricing unit by more than 20% per pricing unit; or
  3. Introduced a new prescription drug for distribution in this State when the wholesale acquisition cost is greater than the amount that would cause the drug to be considered a specialty drug under the Medicare Part D program (hereinafter “new drug”).

MHDO Posting for CY 2021 (baseline data period- 12/31/2020)

Select this link to download the Excel version of the report below.

Table 1. List of brand-name drug NDCs that incurred an increase in the wholesale acquisition cost (WAC) by more than 20% per pricing unit.

List of brand-name drug NDCs that incurred an increase in the wholesale acquisition cost (WAC) by more than 20% per pricing unit

Select this link to download the Excel version of the report below.

Table 2. List of generic drug NDCs that costs at least $10 per pricing unit and incurred an increase in the wholesale acquisition cost (WAC) by more than 20% per pricing unit.

List of generic drug NDCs that costs at least $10 per pricing unit and incurred an increase in the wholesale acquisition cost (WAC) by more than 20% per pricing unit

Select this link to download the Excel version of the report below.

Table 3. List of new prescription drugs where the wholesale acquisition cost (WAC) is greater than the amount to be considered a specialty drug under the Medicare Part D program. Note: Items listed in Table 3 may be packaged such that package contents represent more than a 30-day maximum recommended dosage. Items which fall below the Medicare Part D specialty-tier cost threshold, after application of the 30-day maximum recommended dosage to the WAC value calculated for the lowest dispensable unit of the drug product, will be removed upon notification to MHDO’s Compliance Officer, Philippe Bonneau at philippe.bonneau@maine.gov and MHDO review.

List of new prescription drugs as described above